April 8, 2025—Techcyte, Pramana, and Aiosyn announced a collaboration to integrate AI-powered breast and kidney histopathology analysis directly into the digital pathology workflow. By leveraging Pramana’s Edge AI computing capabilities, Aiosynʼs mitosis counting algorithm and kidney image analysis can be integrated with Pramana scanners. Results are available in Techcyte’s Fusion slide viewer through DICOM annotations.
Aiosyn Mitosis Breast is an IVDR-certified solution for mitosis counting on slides of breast biopsies. The algorithm uses deep learning to detect cell division in whole slide images, aiming to enhance the efficiency and consistency of mitosis analysis for breast cancer grading. Aiosynʼs NephroPath AI delivers precise quantification of kidney structures.
In a separate release, Techcyte announced its collaboration with Aiosyn to bring Aisoynʼs AI algorithms to the Fusion digital pathology platform. Aiosyn QC, an AI-based slide quality control algorithm, detects and highlights common artifacts in H&E and immunohistochemistry slides. The collaboration also brings Aiosyn Mitosis Breast into the Fusion platform.
Fusion is available for research use only in the United States and is CE-IVD marked in the European Union.